Adrenocortical Cancer Cell uptake of Iron Oxide Nanoparticles

Authors

• Ritihaas Surya Challapalli, Discipline of Pharmacology & Therapeutics, School of Medicine, University of Galway, Galway, Ireland.
• Cong Hong, Discipline of Pharmacology & Therapeutics, School of Medicine, University of Galway, Galway, Ireland.
• Anna Sorushanova, Discipline of Pharmacology & Therapeutics, School of Medicine, University of Galway, Galway, Ireland.
• Obdulia Covarrubias-Zambrano, Department of Cancer Biology, The University of Kansas Medical Center, Kansas City, KS. USA.
• Nathan Mullen, Discipline of Pharmacology & Therapeutics, School of Medicine, University of Galway, Galway, Ireland.
• Sarah Feely, Discipline of Pharmacology & Therapeutics, School of Medicine, University of Galway, Galway, Ireland.
• Jose Covarrubias, Department of Cancer Biology, The University of Kansas Medical Center, Kansas City, KS. USA.
• Sunita N. Varghese, Department of Cancer Biology, The University of Kansas Medical Center, Kansas City, KS. USA.
• Constanze Hantel, Department of Endocrinology, Diabetes, and Clinical Nutrition, University Hospital Zurich, Zurich, Switzerland.
• Peter Owens, Centre for Microscopy & Imaging, University of Galway, Ireland.
• Martin O'Halloran, Translational Medical Device Lab, University of Galway, Galway, Ireland.
• Punit Prakash, Department of Electrical and Computer Engineering, Kansas State University, Manhattan, KS. USA.
• Stefan H. Bossmann, Department of Cancer Biology, The University of Kansas Medical Center, Kansas City, KS. USA.
• Michael Conall Dennedy, Discipline of Pharmacology & Therapeutics, School of Medicine, University of Galway, Galway, Ireland.

Document Type

Journal Article

Publication Date

12-7-2024

Journal

bioRxiv : the preprint server for biology

DOI

10.1101/2024.12.04.626790

Keywords

H295R; HAC15; HUVEC; MUC-1; Nanoparticles; iron oxide; monocytes

Abstract

Adrenocortical carcinoma (ACC) is a rare cancer with poor prognosis, treated primarily through surgery and chemotherapy. Other treatments like radiation or thermal ablation for metastases have limited success, and recurrence is common. More effective management options are needed. Magnetic iron oxide nanoparticles (IONP) show promise in cancer treatment due to their ability to be modified for selective uptake by cancer cells. This study investigated IONP uptake in ACC cell lines (H295R, HAC-15, MUC-1) using a multicellular model with endothelial cells (HUVEC) and monocytes. IONP uptake was concentration- and time-dependent, with optimal uptake at 10 μg/mL. IONP were found in the cytoplasm and intracellular vesicles of ACC cells. However, endothelial cells and monocytes also absorbed IONP, reducing uptake by ACC cells. These findings suggest ACC cells actively take up IONP, but better targeting is needed to enhance uptake specificity and efficiency.

APA Citation

Challapalli, Ritihaas Surya; Hong, Cong; Sorushanova, Anna; Covarrubias-Zambrano, Obdulia; Mullen, Nathan; Feely, Sarah; Covarrubias, Jose; Varghese, Sunita N.; Hantel, Constanze; Owens, Peter; O'Halloran, Martin; Prakash, Punit; Bossmann, Stefan H.; and Dennedy, Michael Conall, "Adrenocortical Cancer Cell uptake of Iron Oxide Nanoparticles" (2024). GW Authored Works. Paper 6188.
https://hsrc.himmelfarb.gwu.edu/gwhpubs/6188

Department

Biomedical Laboratory Sciences